Global Information
회사소개 | 문의 | 비교리스트

알레르기성 결막염 : 파이프라인 리뷰

Allergic Conjunctivitis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 192452
페이지 정보 영문 97 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


알레르기성 결막염 : 파이프라인 리뷰 Allergic Conjunctivitis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 97 Pages

알레르기성 결막염은 눈꺼풀 및 백안(결막)을 덮는 조직의 투명층이 꽃가루, 비듬, 곰팡이 및 기타 알레르기 원인 물질에 의해 붓거나 염증 발생시 발병합니다. 증상에는 극심한 가려움, 안검 부종, 결막을 덮고 있는 투명 세포층의 혈관 확대(확장) 및 끈끈한 눈곱이 포함됩니다. 치료에는 항히스타민제 또는 항염증제 요법이 이용됩니다.

세계의 알레르기성 결막염 치료제 파이프라인 제품에 대해 분석했으며, 현재 개발 파이프라인의 상황 및 최신 동향, 후기 단계 및 중지된 프로젝트의 정보, 주요 기업 및 개발중인 제품의 리뷰 등을 정리하여 전해드립니다.

서론

  • 조사 범위

알레르기성 결막염 - 개요

알레르기성 결막염 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 기업에서 개발중인 제품

알레르기성 결막염 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

알레르기성 결막염 치료제 개발에 참여하고 있는 기업

약제 개요

알레르기성 결막염 - 휴지중인 프로젝트

알레르기성 결막염 - 개발이 중지된 제품

알레르기성 결막염 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Allergic Conjunctivitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Allergic Conjunctivitis - Pipeline by Ajanta Pharma Ltd, H1 2020
  • Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H1 2020
  • Allergic Conjunctivitis - Pipeline by Allakos Inc, H1 2020
  • Allergic Conjunctivitis - Pipeline by Allergan Plc, H1 2020
  • Allergic Conjunctivitis - Pipeline by Clevexel Pharma SAS, H1 2020
  • Allergic Conjunctivitis - Pipeline by Dhp Korea Ltd, H1 2020
  • Allergic Conjunctivitis - Pipeline by Eleusis Ltd, H1 2020
  • Allergic Conjunctivitis - Pipeline by iCo Therapeutics Inc, H1 2020
  • Allergic Conjunctivitis - Pipeline by JW Pharmaceutical Corp, H1 2020
  • Allergic Conjunctivitis - Pipeline by Marinomed Biotech AG, H1 2020
  • Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, H1 2020
  • Allergic Conjunctivitis - Pipeline by OKYO Pharma Ltd, H1 2020
  • Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals Inc, H1 2020
  • Allergic Conjunctivitis - Pipeline by RAPT Therapeutics Inc, H1 2020
  • Allergic Conjunctivitis - Pipeline by Re-Pharm Ltd, H1 2020
  • Allergic Conjunctivitis - Pipeline by Sylentis SAU, H1 2020
  • Allergic Conjunctivitis - Dormant Projects, H1 2020
  • Allergic Conjunctivitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Allergic Conjunctivitis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Allergic Conjunctivitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2020, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 2, 8 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Conjunctivitis - Overview
    • Allergic Conjunctivitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Allergic Conjunctivitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Allergic Conjunctivitis - Companies Involved in Therapeutics Development
    • Ajanta Pharma Ltd
    • Aldeyra Therapeutics Inc
    • Allakos Inc
    • Allergan Plc
    • Clevexel Pharma SAS
    • Dhp Korea Ltd
    • Eleusis Ltd
    • iCo Therapeutics Inc
    • JW Pharmaceutical Corp
    • Marinomed Biotech AG
    • Ocular Therapeutix Inc
    • OKYO Pharma Ltd
    • Portola Pharmaceuticals Inc
    • RAPT Therapeutics Inc
    • Re-Pharm Ltd
    • Sylentis SAU
  • Allergic Conjunctivitis - Drug Profiles
    • (alcaftadine + ketorolac tromethamine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGN-229666 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AK-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bertilimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DHPNP-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELE-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketotifen SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OKYO-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRT-2761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • reproxalap - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-0217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPT-193 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYL-116011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tacrolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Allergic Conjunctivitis - Dormant Projects
  • Allergic Conjunctivitis - Discontinued Products
  • Allergic Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Feb 24, 2020: Aldeyra Therapeutics to provide update on late-stage clinical development pipeline at 2020 Research & Development Day
      • Jan 22, 2020: Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study
      • Oct 31, 2019: Aldeyra Therapeutics releases expanded results from allergen chamber trial and announces plans to initiate the phase 3 INVIGORATE trial in patients with Allergic Conjunctivitis
      • Oct 30, 2019: Aldeyra Therapeutics to host conference call and webcast to release expanded results from allergen chamber trial and announce design of Phase 3 INVIGORATE trial in patients with allergic conjunctivitis
      • Oct 23, 2019: Eleusis presents new research on the anti-inflammatory potential of serotonin 2A receptor agonists at the 2019 International Society for Research on Psychedelics
      • Sep 26, 2019: Aldeyra Therapeutics to present phase 3 ALLEVIATE trial results in allergic conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting
      • Sep 24, 2019: Ocular Therapeutix announces first patient dosed in phase 3 clinical trial of DEXTENZA for the treatment of Allergic Conjunctivitis
      • May 07, 2019: Allakos announces positive Results with AK002 in patients with Severe Allergic Conjunctivitis
      • Apr 24, 2019: Ocular Therapeutix to present new data on DEXTENZA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
      • Mar 27, 2019: Aldeyra's ALLEVIATE trial of reproxalap eyedrops meets endpoints
      • Mar 25, 2019: Aldeyra Therapeutics schedules webcast and conference call to announce top-line results from the phase 3 ALLEVIATE trial in Allergic Conjunctivitis
      • Dec 20, 2018: Aldeyra Therapeutics announces last patient dosed in the ALLEVIATE phase 3 clinical trial
      • Nov 28, 2018: Viennese Biotech company Marinomed demonstrates the benefits of its patented Marinosolv Technology of Tacrosolv
      • May 07, 2018: Sylentis announces new data on the treatment of allergic conjunctivitis
      • Apr 24, 2018: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q